Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Standard BioTools ( (LAB) ).
On April 20, 2026, Standard BioTools Inc. disclosed that it had received a notice from Nasdaq stating its shares no longer meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market, after trading below that threshold for 30 consecutive business days. The notice does not immediately affect trading of LAB shares or the company’s operations or SEC reporting, but it starts a 180-day period, through October 19, 2026, for the company to restore compliance by achieving a minimum bid price of at least $1.00 for 10 consecutive business days.
If Standard BioTools regains compliance within the initial 180 days or qualifies for and utilizes an additional 180-day period via transfer to the Nasdaq Capital Market, it can preserve its Nasdaq listing and avoid potential delisting risk. The company signaled an intention to work toward curing the deficiency, potentially including measures such as a reverse stock split, underscoring the importance of maintaining its exchange listing for shareholders and strategic positioning, while cautioning there is no assurance it will succeed within the prescribed timeframe.
The most recent analyst rating on (LAB) stock is a Hold with a $1.35 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The score is held down primarily by weak financial performance—volatile/declining revenue, deep losses, and persistent negative free cash flow. Technicals remain mixed with a negative MACD and price below longer-term averages. The SomaLogic sale is a meaningful positive corporate event that improves liquidity and flexibility, but it does not fully offset the underlying profitability and demand challenges.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. is a life sciences tools company listed on the Nasdaq Global Select Market under the ticker LAB, providing instrumentation and related technologies to researchers and laboratories. The company operates within the broader biotechnology and diagnostics ecosystem, where maintaining a Nasdaq Global Select listing supports access to capital markets and visibility among institutional investors.
Average Trading Volume: 2,286,832
Technical Sentiment Signal: Sell
Current Market Cap: $348.7M
See more insights into LAB stock on TipRanks’ Stock Analysis page.